Antibody-Drug Conjugates (ADC)

Akeso has secured Phase I clinical trial clearance in China for AK158D1, a bispecific antibody drug conjugate targeting EGFR and TROP2 in advanced solid tumors. The clearance puts fresh attention on the company's pipeline as it pushes deeper into IO2.0 and ADC2.0. Akeso's shares recently traded at HK$90.5, up 3.37% over 90 days but down 20.12% year to date, against a consensus analyst price target of HK$158.28, with the most bullish target at HK$226.04 and the most bearish at HK$125.08. The company remains exposed to execution setbacks given its reliance on a handful of key drugs and a current net loss of CN¥967.2 million.

Merck received a positive opinion from the European Medicines Agency's CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with resectable muscle-invasive bladder cancer in the European Union. If endorsed by the European Commission, the regimen would be the first PD-1 inhibitor plus antibody-drug conjugate option for this setting in Europe. The addressable group in Europe is relatively concentrated but clinically high need, with bladder cancer cases estimated at about 224,700 in 2022, roughly 25% of them classified as muscle invasive. The key near-term marker is the European Commission ruling expected by the fourth quarter of 2026, since the CHMP only issues recommendations.

AstraZeneca and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy, with 14.3 months median progression free survival and a 37% risk reduction versus pembrolizumab plus chemotherapy. Long-term follow-up data for TAGRISSO indicated eight-year survival benefits in early-stage EGFR-mutated lung cancer patients already on treatment protocols. Tozorakimab emerged as the first biologic to show efficacy in reducing exacerbations across a broad chronic obstructive pulmonary disease population in late-stage trials, with a 29% to 34% exacerbation reduction. Management has pointed to more than US$10b in potential peak risk adjusted revenue from new drugs, and investors will focus on US and EU COPD approval decisions ahead of the first quarter of 2027 Prescription Drug User Fee Act date. The article was produced by Simply Wall St.

AstraZeneca secured a major access win for Enhertu in England after the NHS reversed an earlier cost-effectiveness rejection, Reuters reported Thursday. Roughly 1,000 women a year could now become eligible for Enhertu to treat HER2-low metastatic breast cancer. The drug carries a published British price of 1,455 per 100-milligram vial, but AstraZeneca, Daiichi Sankyo and NICE did not disclose the economics of the reimbursement agreement. Earlier clinical evidence showed the therapy extending survival by around six months for some patients, giving the NHS a meaningful clinical case to reconsider access. The decision could also help expand access in Wales and Northern Ireland, widening Enhertu's commercial reach across the U.K., though the confidential discount, treatment duration and patient persistence will ultimately determine how much of the expanded access flows through to AstraZeneca's bottom line.

AstraZeneca shares rose 2.16% intraday after J.P. Morgan reiterated an Overweight rating, citing six Phase III readouts due in 2027 that together carry more than $10 billion in risk-adjusted peak sales and should improve confidence in the company's ability to keep growing beyond 2030. For laroprovstat, an oral PCSK9 inhibitor reading out in the first quarter of 2027, the bank models peak risk-adjusted sales of $3.2 billion against consensus of $2.4 billion, noting the drug showed a smaller LDL-C reduction than Merck's Lipfendra in earlier testing but carries no fasting requirement, which J.P. Morgan sees as the more important difference. On the bank's numbers, zibotentan with Farxiga in kidney disease gets an 80% probability of success on comparable earlier results, while balcinerenone with Farxiga in heart failure gets 50% because its partial mineralocorticoid receptor antagonism could dilute the benefit rivals have shown. In oncology, Datroway in triple-negative breast cancer and puxi-sam in endometrial cancer both carry 80%, and saruparib in prostate cancer is judged strong enough in the 30% of trial patients with HRR mutations to de-risk $3 billion of peak sales.

Whitehawk Therapeutics announced two real-world analyses supporting PTK7 as a durable and clinically relevant ADC target in pretreated, EGFR wild-type non-small cell lung cancer, presented at the IASLC 2026 World Conference on Lung Cancer in Seoul. In tumor samples from patients with EGFR wild-type lung adenocarcinoma, PTK7 expression remained largely stable following standard-of-care chemotherapy and immunotherapy and showed less treatment-associated variation than several late-stage ADC targets including MET, PD-L1 and ITGB6, with expression generally consistent across tumors with or without other actionable genomic alterations such as KRAS G12C, ALK and MET. A separate analysis found real-world overall survival was not impacted by PTK7 expression, supporting PTK7 as a target-engagement biomarker independent of prognosis. The findings reinforce the scientific rationale for HWK-007, Whitehawk's next-generation PTK7-directed ADC in Phase 1 development for non-squamous EGFR wild-type NSCLC, platinum-resistant ovarian cancer and endometrial cancer. The analyses were conducted under a previously announced collaboration between Whitehawk and Tempus AI.

CSPC Innovation Pharmaceutical Co., Ltd. announced on September 14, 2026 that its controlling subsidiary CSPC Megalith Biopharmaceutical Co., Ltd. presented Phase I/II clinical study data for SYS6010 combined with enlonstobart injection in an oral presentation at the 2026 World Conference on Lung Cancer. The study was led by Professor Zhou Caicun of Shanghai East Hospital, evaluating the safety, tolerability, and preliminary efficacy of SYS6010, an EGFR-targeting ADC, combined with enlonstobart, a PD-1 inhibitor, with or without chemotherapy in patients with EGFR and ALK wild-type advanced non-small cell lung cancer and other conditions. As of July 13, 2026, a total of 123 patients with untreated driver-gene-negative advanced non-small cell lung cancer were enrolled across two dosing regimens, with a median follow-up of 10.8 months. In terms of safety, the incidence of grade 3 or higher treatment-related adverse events was 51.6% and 52.5% for the two regimens, respectively, and the incidence of adverse events leading to discontinuation was 9.7% and 8.2%, respectively. In terms of efficacy, the confirmed objective response rates in the overall population were 58.9% and 49.2%, respectively, and the ORRs in patients with high PD-L1 expression were 77.8% and 82.4%, respectively. Among patients with high PD-L1 expression and non-squamous histology, the ORRs reached 81.8% and 91.7%, respectively. The combination therapy has now entered Phase III clinical trials, and the company cautioned that innovative drug development involves high investment, high risk, and long cycles, and will not have a significant impact on performance in the short term.

Roche announced that its collaborator MediLink released interim results from the randomized phase III TAISHAN-302 trial showing that Tam-Peli, also known as tambotatug pelitecan or YL201, beat topotecan in Chinese patients with relapsed small-cell lung cancer who progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor. The trial met its primary endpoint of overall survival, with Tam-Peli reducing the risk of death by 54 percent, with median overall survival of 13.3 versus 9.4 months and a stratified hazard ratio of 0.46 at a p-value below 0.0001. Tam-Peli also extended median progression-free survival to 7.4 months from 2.8 months and achieved a confirmed objective response rate of 59.1 percent versus 9.7 percent. The results are being presented as a Late-Breaking Abstract during a Presidential Presentation at the IASLC 2026 World Conference on Lung Cancer in Seoul with simultaneous publication in The New England Journal of Medicine, and China's Center of Drug Evaluation has accepted the New Drug Application for filing. Roche, which holds development, manufacturing and commercialization rights for Tam-Peli worldwide outside mainland China, Hong Kong and Macau under a January 2026 exclusive licensing agreement with MediLink Therapeutics, said the data support plans to rapidly initiate global phase III trials.

HUTCHMED has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, in a deal worth up to approximately $1.3 billion. The agreement includes a $110 million upfront payment and potential tiered royalties, with HUTCHMED leading global Phase I development before GSK assumes responsibility outside China. HMPL-A830 is designed to target EGFR-overexpressing tumor cells and deliver a KRAS payload, potentially addressing resistance to standalone KRAS inhibitors in colorectal, pancreatic, and lung cancers. HUTCHMED also granted GSK a right of first negotiation on another early-stage candidate from its ATTC platform. The company expects to present detailed data from two positive Phase III trials with AstraZeneca at a future conference, and anticipates milestone and royalty income from commercialized indications, including tiered royalties of 9% to 13% on global sales for the SAFFRON trial and 30% royalties from AstraZeneca for specified indications in China.

DelveInsight forecasts that the osteosarcoma market across the seven major markets—the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan—will grow at a CAGR of 9% from approximately USD 60 million in 2025 through 2036, driven by eight emerging therapies including OST-HER2, DANYELZA, Vactosertib, and Risvutatug rezetecan. OST-HER2, developed by OS Therapies, is a HER2-targeted immunotherapy that has received FDA Fast Track and Orphan Drug Designations, with a planned Biologics License Application under the Accelerated Approval pathway in the second half of 2026, and is projected to generate about USD 37 million across the 7MM by 2036. Other notable candidates include SERB Pharmaceutical's DANYELZA, an anti-GD2 antibody with a niche profile, and GSK's Risvutatug rezetecan, an ADC targeting B7-H3 that received Breakthrough Therapy Designation in 2025. The pipeline remains concentrated in early-stage trials, with limited late-stage data posing challenges for regulatory approval, but increasing research in targeted and immunotherapies is expanding the landscape.

AstraZeneca has received European Union approval for a first-line Enhertu plus pertuzumab combination for HER2-positive breast cancer, marking the first new first-line regimen in over a decade, and has completed a global license agreement for lung cancer drug ZEGFROVY, securing worldwide rights to a next-generation EGFR inhibitor with breakthrough designations. These oncology milestones expand AstraZeneca's approved treatment options in breast cancer and reinforce its position in lung cancer. The company, a £185.7 billion biopharmaceutical firm, is using its antibody drug conjugate and targeted therapy platforms to deepen its presence in these large global markets. The news supports the narrative that new oncology medicines could collectively add more than $10 billion in peak risk-adjusted revenue, though it also highlights reliance on partnered assets and the need to earn returns on sizeable outlays such as the $600 million upfront ZEGFROVY payment and future milestones. Investors will watch for how quickly Enhertu uptake in the EU shows up in reported sales and whether AstraZeneca provides timelines for ZEGFROVY development.

The European Commission has approved Enhertu in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer, marking the first new regimen in over a decade for this indication. The approval is based on the DESTINY-Breast09 phase 3 trial, which showed that the combination reduced the risk of disease progression or death by 44% versus THP, with a median progression-free survival of 40.7 months compared to 26.9 months. This is the second approval for Enhertu in the EU in two months, following a recent tumor-agnostic approval. Daiichi Sankyo and AstraZeneca jointly developed the drug, and AstraZeneca will pay Daiichi Sankyo a $100 million milestone payment following this approval. The combination is now approved in more than 40 countries worldwide for this indication.

CSPC Innovation Pharmaceutical Co., Ltd. announced that SYS6010, developed by its controlling subsidiary CSPC Megalith Biopharmaceutical Co., Ltd., has been included in the breakthrough therapy designation list by the Center for Drug Evaluation of the National Medical Products Administration. The proposed indication is for patients with recurrent or metastatic head and neck squamous cell carcinoma who have failed immunotherapy and platinum-based chemotherapy. SYS6010 is an antibody-drug conjugate targeting EGFR, composed of a humanized anti-EGFR monoclonal antibody linked to a topoisomerase I inhibitor payload via a cleavable linker. According to GLOBOCAN 2024 estimates, head and neck squamous cell carcinoma accounts for approximately 845,000 new cases and 392,000 deaths globally each year, with a five-year overall survival rate of only 40 to 50 percent. A pivotal Phase III clinical trial of SYS6010 monotherapy for this indication is currently underway. The drug has previously received two breakthrough therapy designations, for EGFR-mutant non-small cell lung cancer and esophageal squamous cell carcinoma. After inclusion in the breakthrough therapy designation list, the Center for Drug Evaluation will prioritize resources and strengthen guidance. However, the company cautioned that drug development involves high investment, high risk, and long cycles, and will not have a significant impact on short-term performance.

Pfizer's oncology segment, which accounts for about 27% of total revenues, posted a 3% increase to $4.17 billion in the second quarter of 2026, driven by strong sales of Padcev, Lorbrena, and Braftovi/Mektovi. Padcev sales climbed 23% to $667 million, benefiting from market share gains in first-line metastatic urothelial cancer and the recent FDA approval for muscle-invasive bladder cancer, which expanded its addressable market to more than 42,000 U.S. patients. The company is also advancing its pipeline, including PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from 3SBio, with pivotal phase III studies in colorectal and lung cancers. Pfizer expects to have eight or more blockbuster oncology medicines by 2030, while competitors like J&J, AstraZeneca, and Merck also report strong oncology growth. Pfizer's stock trades at 9.48 forward earnings, below the industry's 18.71, and the Zacks Consensus Estimate for 2026 EPS has risen to $2.98.

AstraZeneca has reported positive high-level results from several late-stage oncology and immunology trials, including TEZSPIRE in eosinophilic esophagitis, which met key clinical goals. The DESTINY-Lung04 and SAFFRON trials in non-small cell lung cancer also showed encouraging progress. As part of pipeline prioritisation, the company has initiated a pivotal Phase 3 trial of Datroway in high-risk muscle-invasive urothelial cancer and terminated an underperforming lung cancer study. These developments support AstraZeneca's strategy to expand its treatment portfolio in serious diseases, with management estimating that new medicines could generate over $10 billion in peak risk-adjusted revenue. The company, with a market cap of £187.9 billion, is focusing on antibody-drug conjugates and complex immunology biologics to counter patent and pricing pressures on existing blockbusters.

Gilead Sciences received expanded European Commission approval for Trodelvy in combination with Keytruda as a first-line treatment for metastatic triple-negative breast cancer across PD-L1 status in Europe, making it the first antibody-drug conjugate and immunotherapy combination approved for this indication in the European Union. The decision broadens Trodelvy's addressable patient population in Europe and advances Gilead's oncology portfolio, which is part of its broader strategy to diversify beyond HIV. The company, with a market cap of about $183.6 billion, now faces the test of translating this approval into sustained demand, with analysts watching for updates on oncology's share of product sales in upcoming earnings reports.

Asieris Pharmaceuticals announced that its controlling subsidiary Jiangsu Beilian Biotechnology received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. Its independently developed APL-2501, with the compound name BLB101, has been approved to conduct clinical trials for advanced solid tumors. The drug is an anti-CLDN6/9 antibody-drug conjugate and is expected to be used for treating various advanced solid tumors including ovarian cancer and non-small cell lung cancer. This approval has no significant impact on the company's near-term performance.

Huadong Medicine announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. has received Fast Track designation from the U.S. FDA for its self-developed injectable HDM2005, intended for the treatment of relapsed or refractory mantle cell lymphoma. This drug is the first ROR1-targeting antibody-drug conjugate in development in China to receive this designation, and clinical development is currently underway across multiple indications for malignant tumors.

Baili Tianheng announced that its first-in-class EGFR and HER3 bispecific antibody-drug conjugate Izalontamab met the primary endpoint of progression-free survival in a Phase III clinical trial for HR-positive, HER2-negative breast cancer. The trial enrolled patients with unresectable locally advanced, recurrent, or metastatic HR-positive, HER2-negative breast cancer who had failed at least one prior line of chemotherapy, and the independent data monitoring committee determined at a prespecified interim analysis that the primary endpoint was met. Izalontamab is the world's first and only approved bispecific antibody-drug conjugate, having received NMPA approval for two indications: nasopharyngeal carcinoma and esophageal squamous cell carcinoma. A new drug application for triple-negative breast cancer has been accepted by the CDE. To date, the drug has been studied in more than 40 clinical trials in China and the United States, including 20 Phase III trials. Seven indications have received breakthrough therapy designation from the CDE, two have received priority review, and one has received breakthrough therapy designation from the US FDA. The company noted that the drug must complete clinical trials and obtain regulatory review and approval before it can be marketed and sold.

Rongchang Bio released its 2026 interim report, with net profit attributable to the parent turning from a loss of 450 million yuan in the same period last year to a profit of 4.66 billion yuan. The company's first-half operating revenue was 5.85 billion yuan, up 433.1 percent year-on-year; non-GAAP net profit attributable to the parent was 4.34 billion yuan, compared with a loss of 446 million yuan in the same period last year; net operating cash flow was 4.214 billion yuan, up 1,816.2 percent year-on-year. Second-quarter operating revenue was 5.2 billion yuan, up 808.6 percent year-on-year, and net profit attributable to the parent was 4.33 billion yuan. The company said sales revenue from its core products telitacicept and disitamab vedotin continued to grow, while the exclusive license agreement for RC148 signed with AbbVie brought substantial technology licensing revenue.

BioNTech SE has already presented new clinical data from its broad lung cancer pipeline at the 2026 IASLC World Conference on Lung Cancer in Seoul, covering key assets pumitamig, gotistobart and several mRNA-based immunotherapy approaches. The company's first-in-class combination data pairing its PD-(L)1 x VEGF bispecific antibody pumitamig with a B7H3-targeted antibody-drug conjugate underscores BioNTech's push into differentiated, novel-novel immunotherapy regimens in lung cancer. The new WCLC lung cancer data reinforces that pivot but does not, by itself, change the near term reality that BioNTech is unprofitable, dependent on pipeline progress, and exposed to the risk that key late stage trials fail to convert into meaningful non COVID revenue. Among recent developments, the May 30 ROSETTA Lung program update on pumitamig stands out alongside the new pumitamig plus B7H3 ADC data, framing a clearer near term catalyst path in lung cancer around multiple Phase 3 readouts. BioNTech's narrative projects €2.2 billion revenue and €374.5 million earnings by 2029, while the most pessimistic analysts once modeled a 25.6% annual drop to about €1.1 billion by 2029.

AbbVie announced it will present new data across its lung cancer pipeline at the 2026 World Conference on Lung Cancer, including Phase 1b results for its PD-1/VEGF bispecific antibody ABBV-1480 in frontline non-small cell lung cancer. At the 10 mg/kg dose, the objective response rate was 90.0% in squamous NSCLC and 75.9% in non-squamous NSCLC, with no grade 3 or higher hemorrhages observed. The company will also share updates on telisotuzumab adizutecan and ABBV-706, an investigational SEZ6-targeted antibody-drug conjugate that previously demonstrated an 82% objective response rate in relapsed/refractory small cell lung cancer. AbbVie said the presentations reflect its strategy to build a lung cancer portfolio spanning next-generation immunotherapies, targeted ADCs, and potential novel combinations.

Morgan Stanley upgraded Merck to Overweight and more than doubled its price target to $89 from $39 after positive Phase 3 data for the personalized melanoma vaccine intismeran autogene, which Merck is developing with Moderna. The firm cited stronger assumptions for intismeran and encouraging prospects for sac-TMT, an antibody-drug conjugate being studied in lung and endometrial cancers, and raised its valuation multiple to 17 times earnings from 11 times. RBC Capital Markets took the opposite view, downgrading Merck to Sector Perform from Outperform while raising its target to $150 from $142, arguing the valuation already reflects much of the pipeline optimism. The debate centers on whether Merck's pipeline can replace enough of Keytruda's future revenue before the 2028 loss of exclusivity, with Morgan Stanley's base case now implying flattish revenues versus a prior 5% decline following the Keytruda patent cliff.

AstraZeneca reported positive late-stage results for TAGRISSO plus savolitinib in the SAFFRON Phase III trial in difficult-to-treat non-small cell lung cancer. ENHERTU met key goals in the DESTINY-Lung04 Phase III trial with survival benefits in NSCLC patient groups with limited options. The company discontinued development of lung cancer candidate volrustomig after trial results showed a lack of efficacy. These moves highlight how fast lung cancer treatment and related technologies are changing.

AstraZeneca and Daiichi Sankyo announced that ENHERTU demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus the global standard of care in the DESTINY-Lung04 Phase III trial for first-line treatment of HER2-mutant advanced non-small cell lung cancer. The trial compared ENHERTU against platinum-pemetrexed doublet chemotherapy plus pembrolizumab in 454 patients with unresectable, locally advanced or metastatic non-squamous NSCLC. ENHERTU is the first and only HER2-directed medicine to improve progression-free survival over the standard of care in this setting, and the safety profile was consistent with its known profile with no new safety concerns. The data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.

Akeso secured regulatory approval in China for ivonescimab plus chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer. The company also started a new Phase II study of its bispecific ADC candidate AK146D1 in combination with ivonescimab for patients with advanced breast cancer. Akeso is a Hong Kong-based biopharmaceutical company with a HK$95.4 billion market cap focused on antibody drugs. The approval positions the ivonescimab combination as a new standard of care for advanced squamous NSCLC.

RemeGen has disclosed its 2026 interim results forecast, expecting first-half operating revenue of approximately 5.85 billion yuan, an increase of about 4.75205 billion yuan compared with the same period in 2025, representing year-on-year growth of roughly 433 percent. The company expects net profit attributable to owners of the parent of about 4.7 billion yuan for the first half, swinging to a profit; net profit after deducting non-recurring items is expected to be about 4.3 billion yuan, also swinging to a profit. The significant change in performance is mainly due to continued growth in domestic sales revenue of its core products telitacicept and disitamab vedotin, as well as substantial technology licensing revenue from an exclusive license agreement for RC148 signed with a holding company of AbbVie. The financial data in this forecast are only preliminary estimates and have not yet been audited by certified public accountants.